|Day Low/High||5.56 / 5.85|
|52 Wk Low/High||3.43 / 19.80|
Investors in Galena Biopharma Inc saw new options begin trading today, for the March 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GALE options chain for the new March 27th contracts and identified the following put contract of particular interest.
Trade-Ideas LLC identified Galena Biopharma (GALE) as a weak on high relative volume candidate
Investors in Galena Biopharma Inc saw new options become available today, for the February 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GALE options chain for the new February 27th contracts and identified the following put contract of particular interest.
Company Anticipates Multiple Key Milestones Across Its Commercial and Clinical Portfolio
Another crazy and profitable year in biotech investing was captured 140 characters at a time.
Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
Biotech columnist Adam Feuerstein answers readers' questions about health care.
The scandal-ridden Galena, still under active SEC investigation, was unable to muster sufficient interest from institutional investors.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.